THE NATURAL-HISTORY OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN PATIENTS WITH AIDS

被引：77

作者：

FONG, IW ^{[1
]}

TOMA, E ^{[1
]}

CAMERON, DW ^{[1
]}

GENEREAUX, M ^{[1
]}

BERGER, P ^{[1
]}

KRAJDEN, S ^{[1
]}

CLARKE, S ^{[1
]}

CHAN, R ^{[1
]}

SENAY, H ^{[1
]}

LANDIS, S ^{[1
]}

SALIT, I ^{[1
]}

SIMOR, A ^{[1
]}

GILL, J ^{[1
]}

机构：

[1] UNIV MONTREAL,HOTEL DIEU,MONTREAL,PQ,CANADA

来源：

CLINICAL INFECTIOUS DISEASES | 1995年 / 20卷 / 05期

关键词：

D O I：

10.1093/clinids/20.5.1305

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Progressive multifocal leukoencephalopathy (PML) is usually a fatal neurological disease, The natural history of PML in patients with human immunodeficiency virus infection was analyzed, The correlations between CD4+ lymphocyte count, previous diagnosis of AIDS, treatment with cytarabine, and survival time are reported for 28 individuals for whom the diagnosis of PML was confirmed by histopathologic examination, For 16 patients (57%), PML was the AIDS-defining illness, For these 16 patients, the mean (+/-SD) survival time after presentation was 7.5 +/- 7.6 months (range, 1-31 months), whereas that for the 12 patients (43%) for whom AIDS was previously diagnosed was 3.2 +/- 2.8 months (range, 1-11 months) (P =.01), The overall mean (+/-SD) CD4+ cell count was 85 +/- 82/mm(3) (range, 12-349/mm(3)), The mean (+/-) survival time for patients with CD4+ cell counts of greater than or equal to 90/mm(3) at the time of presentation was 9.4 +/- 8.7 months, while that for patients with CD4+ cell counts of <90/mm(3) at the time of presentation was 3.6 +/- 1.8 months (P =.03), The nine patients did not benefit from treatment with cytarabine.

引用

页码：1305 / 1310

页数：6

共 31 条

[1] Krupp L.B., Lipton R.B., Siverdlow M.L., Leeds N.E., Llena J., Progressive multifocal leukoencephalopathy: Clinical and radiographic features, Ann Neurol, 17, pp. 344-349, (1985)
[2] Berger J.R., Kaszovitz B., Post M., Dickinson G., Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection, Ann Intern Med, 107, pp. 78-87, (1987)
[3] Astrom K.E., Mancall E.L., Richardson E.P., Progressive multifocal leu koencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkins disease, Brain, 81, pp. 93-111, (1958)
[4] Zu Rhein G.M., Chou S.M., Particles resembling papova viruses in human cerebral demyelinating disease, Science, 148, pp. 1477-1479, (1965)
[5] Silverman L., Rubinstein L.J., Electron microscopic observation on a case of progressive multifocal leukoencephalopathy, Acta Neuro- Pathol (Berl), 5, pp. 215-224, (1965)
[6] Padgett B.L., Walker D.L., Zu Rhein G.M., Ecknoade R.J., Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy, Lancet, 1, pp. 1257-1260, (1971)
[7] Padgett B.L., Walker D.L., Natural History of Human Polyomavirus Infec Tions, pp. 751-758, (1978)
[8] McCance D.J., Persistence of animal and human papovavirus in renal and nervous tissues, Polyoma Viruses and Human Neurological Diseases, pp. 343-357, (1983)
[9] Berger J.R., Mucke L., Prolonged survival and partial recovery in AIDS- associated progressive multifocal leukoencephalopathy, Neurology, 38, pp. 1060-1065, (1988)
[10] Nicoli F., Chauve B., Peragut J.C., Gastaut J.L., Efficacy of cytarabine in progressive multifocal leukoencephalopathy in AIDS [letter], Lancet, 339, (1992)

← 1 2 3 4 →